Occlutech ASD Occluder; Occlutech Pistol Pusher (OPP); Occlutech ASD Occluder Procedure Pack
Occlutech Holding AG · Decision date Nov 24, 2025
What did the FDA approve?
FDA records P200032/S003 as a supplement to PMA P200032, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 24, 2025.
FDA approval order statement
Approval for a change in the minimum recommended French sizes of the Occlutech Delivery Set III (ODS III) compatible with most Occlutech ASD Occluder sizes
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 24, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P200032/S003
- Regulatory pathway
- PMA supplement
- Applicant
- Occlutech Holding AG
- Product code
- OZG
- Decision code
- APPR
- Decision date
- Nov 24, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Transcatheter septal occluder (atrial).
- Applicant
- Occlutech Holding AG
- Product code
- OZG
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P200032/S003 received
Application receipt date recorded by FDA.
P200032/S003 · FDA decision
Real-Time Process
P200032/S004 · Related supplement
Occlutech ASD Occluder; Occlutech Pistol Pusher (OPP); Occlutech ASD Occluder Procedure Pack
P200032/S005 · Related supplement
Occlutech Pistol Pusher
P200032/S006 · Related supplement
Occlutech ASD Occluder and Occlutech Pistol Pusher
Timeline entries are records held by MedtechLedger for P200032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Occlutech Holding AG | PMA supplement | Dec 18, 2025 | FDA | |
Occlutech Pistol PusherP200032/S005 | Occlutech Holding AG | PMA supplement | May 11, 2026 | FDA |
| Occlutech Holding AG | PMA supplement | Jun 5, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Occlutech Holding AG
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Feldstrasse 22, Schaffhausen, 8200
Sources and methodology
- Original FDA record: P200032/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

